Presentation
Topics Covered
We invite you to learn more about:
- Current treatment options for patients living with ALL
- The impact of minimal residual disease (MRD)
- Clinical trials and emerging therapies for ALL treatment
- The importance of open communication with your healthcare team to promote a better quality of life
Program Support
Support for this program provided by AMGEN
Speaker
Daniel J. DeAngelo, M.D., Ph.D.
Adult Leukemia Program
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
For any questions or comments about this program, please email [email protected].